New drug combo aims to tackle resistant Hodgkin's lymphoma

NCT ID NCT05355051

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether combining two drugs—azacitidine and pembrolizumab—can help people with Hodgkin's lymphoma that has come back or stopped responding to treatment. About 24 participants will receive both drugs by IV. The main goal is to see how many patients respond to the combination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: azacitidine and pembrolizumab (given by IV)
What this could lead to: If successful, this combination could offer a new treatment option for patients whose Hodgkin's lymphoma has returned or not responded to prior therapy.
What could go wrong: This is a small, early-phase trial with only 24 participants, so results may not apply broadly. The combination may cause side effects and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN'S LYMPHOMA

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.